reports
Agenus Inc: 1 director
A director at Agenus Inc bought 500,000 shares at 0.648USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and...
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in a total of more than 300 patientsRandomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer,...
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash ...
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement Conference Call Cancelled LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its conference call on Monday, March 13th to discuss its minority cash holdings at Silicon Valley Bank (SVB) in light of the government’s SVB deposit access announcement. About Agenus...
Agenus Schedules Conference Call to Discuss the Company’s Minority Cas...
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it will hold a conference call to provide detail and to answer any questions regarding its minority cash holdings at Silicon Valley Bank (SVB) at 8:30 a.m. ET on Monday, March 13th. Conference CallDial-in numbers: (646) 307...
Agenus to Present Botensilimab Data in Oral Plenary Session at the Soc...
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in Tampa, FL. Updated data from an expansion...
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022...
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced the Company will release its fourth quarter and full year 2022 financial results before the market opens on Tuesday, March 14, 2023. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and ...
Agenus to Participate in February Investor Conferences
Agenus to Participate in February Investor Conferences LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, will participate in the following upcoming investor conferences: Guggenheim 5th Annual Oncology Day – Fireside chat presentation will be held in-person on Thursday, February 9th, 2023 at 9:35 AM ETSVB Securities Global Biopharma Conference – Fireside chat pres...
Agenus Presents Clinical Data Demonstrating Durable Responses of Boten...
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for standard of care and other investigational therapiesResponses have been durable with 69% ongoing at data cut-off; median overall survival not reachedGlobal, randomized Phase 2 trials of botensilimab/balstilimab in MSS CRC and other i...
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Con...
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on Wednesday, January 18th at 11:30am ET. Registration for the webcast can be accessed at . Following the webcast, an archived version will be ...
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at A...
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- . (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in combination with balstilimab at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI), to be held January 19-21, 2023, in San Francisco, CA. Expanded data from the microsatellite stable colorectal (MS...
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Boten...
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapyPatient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4 patients with visceral angiosarcoma67% of patient responses have exceeded one year and remain ongoing at data cut-offPhase 2 trial of botensilimab/balstilimab in sarcomas planned for 2023 L...
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 12:35pm ET. The Conference will be held virtually from November 29th – December 1st, during which Agenus will host one-on-one m...
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab /...
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC)Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS-CRC and advanced melanoma; pancreatic cancer to follow before year-end LEXINGTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disea...
Agenus Provides Corporate Update and Third Quarter 2022 Financial Repo...
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingInitiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and advanced melanomaR&D Event (“The Road Taken”) focused on lead clinical-stage assets to be held November 12 in BostonEnded quarter with $218 million in cash, cash equivalents and short-term investments LEXINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIR...
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Re...
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical experience to date and expected development plans for botensilimab in cold tumors LEXINGTON, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company wil...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIM...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe disease (94.1%), adults aged 70-79 years (93.8%) and those with underlying comorbidities (94.6%)Regulatory filings anticipated in the second half of 2022; if approved, GSK’s RSV older adult vaccine candidate would be one of three appr...
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in...
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline Glioblastoma (GBM) patients following primary tumor resection and radiotherapyRecurrent GBM Development: In the ongoing Phase 2a study, one recurrent GBM patient remains on protocol beyond two and a half years with ...
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
Agenus to Host “The Road Taken” R&D Event on November 12, 2022 LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will host an in-person and virtual Research & Development event (“The Road Taken”) on Saturday, November 12, 2022, from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA. The Road Taken will feature both key opinion leaders at the forefront of immunotherapy development for cancer and ...
Agenus to Present Botensilimab Data at a Plenary Session of the Societ...
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Clinical data in nine cancer indications from trial with 264 patients accruedPlenary discussion relating to expansion cohorts represent heavily pretreated patientsAdditional SITC presentations cover 1) botensilimab’s differentiated mechanism; 2) Phase 2 trial of anti-CD73-TGFβ-trap bifunctional antibodyDhan Chand, PhD, Agenus’ Head of Drug Discovery, to present at SITC Targets for Cancer IO Series LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: AGEN...
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS ...
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with balstilimab (PD-1), has demonstrated in nine treatment-resistant tumor types, including LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the initiat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.